Related Experiment Video
Updated: Jan 14, 2026
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Trends and Outcomes of Anticoagulation for Post-Operative Atrial Fibrillation After Coronary Artery Bypass Graft
Daniel S Cheah1, Kathryn Tsai1, Krishna Prasad Kurpad2
1Carle Illinois College of Medicine, Urbana, Illinois, USA.
Insights
Oral anticoagulation (OAC) after coronary bypass grafting (CABG) for new-onset postoperative atrial fibrillation (POAF) shows reduced mortality at 60 days but no difference in thromboembolism. Long-term OAC benefits remain unclear.
Area of Science:
- Cardiology
- Vascular Surgery
- Pharmacology
Background:
- Postoperative atrial fibrillation (POAF) after coronary artery bypass grafting (CABG) presents management challenges.
- Current guidelines recommend 60-day oral anticoagulation (OAC) for POAF, a shift from previous physician discretion.
- The optimal anticoagulant strategy for POAF post-CABG to prevent stroke is under investigation.
Purpose of the Study:
- To evaluate the effectiveness of different anticoagulant regimens in reducing stroke rates among POAF patients post-CABG.
- To compare complication rates between patients on direct oral anticoagulation (DOAC), warfarin, and no anticoagulation (NA).
Main Methods:
- Utilized the Epic Cosmos database for a retrospective study of US patients undergoing CABG (2017-2023).
- Excluded patients with concomitant aortic/mitral valve replacement.
- Analyzed demographics and complication rates, focusing on POAF incidence and outcomes with OAC (DOAC or warfarin) versus NA.
Main Results:
- Out of 147,546 patients, 7.6% developed POAF.
- OAC use in POAF patients was linked to decreased all-cause mortality at 60 days, with no significant difference in thromboembolism rates.
- At 12 months, no significant differences in all-cause mortality or thromboembolism were observed between OAC and NA cohorts.
Conclusions:
- Long-term anticoagulation with warfarin or DOAC for POAF post-CABG does not appear to reduce thromboembolic events.
- While OAC showed a short-term mortality benefit at 60 days, this did not persist at 1 year.
- The overall benefit of long-term anticoagulation for POAF following CABG remains uncertain.
Background:
The benefit of oral anticoagulation (OAC) in patients with new-onset postoperative atrial fibrillation (POAF) after coronary bypass grafting remains uncertain. The 2023 American Heart Association (AHA) and the American College of Cardiology (ACC) guidelines recommend 60 days of anticoagulation for POAF, whereas management was previously left to the physician's discretion. The aim of this study is to identify the most effective anticoagulant regimens for reducing stroke rates in POAF patients after coronary artery bypass grafting (CABG).
Methods:
Using the Epic Cosmos database, we included all US patients who underwent CABG without concomitant aortic/mitral valve replacement (MVR) from 2017 to 2023. Primary outcomes include demographics of POAF/non-POAF patients and complication rates among patients without anticoagulation, on direct oral anticoagulation (DOAC), or on warfarin.
Results:
Of the 147,546 patients studied, 7.6% (11,336) developed POAF. At 60 days, the use of OAC for POAF was associated with a decrease in all-cause mortality without any difference in thromboembolism rates. At 12 months, there was no difference between all-cause mortality and thromboembolism rates between the OAC and the no anticoagulation (NA) cohorts.
Conclusions:
The benefit of long-term anticoagulation of POAF following CABG with warfarin or DOAC remains unclear, as there was no reduction in thromboembolic events with anticoagulation despite a reduction in all-cause mortality at 60 days. No significant reduction in thromboembolic events or all-cause mortality was exhibited at 1 year. Thus, the benefit of long-term anticoagulation of POAF following CABG with warfarin or DOAC remains unclear.
Related Concept Videos
01:23Peripheral Artery Disease V: Postoperative Nursing Management
01:29Venous Thrombosis III: Interprofessional Care
01:22Aneurysm IV: Nursing Management
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:28Cardiomyopathy VII: Pre and Post Operative Nursing Management